AZM198

AZM198 is a selective, orally active, and irreversible MPO inhibitor with an IC50 of 15.0 nM. AZM198 has an IC50 of 19 μM for CYP3A4. AZM198 has favorable lipophilicity, membrane permeability, metabolic stability, safety, and pharmacokinetic properties. AZM198 exhibits activity in improving vascular function, atherosclerotic plaques, pulmonary hypertension, kidney disease, visceral inflammatory fat deposition, ectopic fat deposition, and hepatic fibrosis[1].

1933460-23-1

12352005

H302-H315-H319-H335

Cytochrome P450; Glutathione Peroxidase

Apoptosis; Metabolic Enzyme/Protease

Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease

O=C1NC(N(CC2=CC=C(C=C2CN)Cl)C3=C1NC=C3)=S

C14H13ClN4OS

320.80

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

[1]Inghardt T, et al. Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction. J Med Chem. 2022 Sep 8;65 (17) :11485-11496.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W996116/

Reference compound1

No Development Reported

CYP3